3 October 2018 - A new arthritis drug that could drastically eliminate chronic and debilitating pain will be made available at a fraction of the cost.

The life-changing treatment for severe inflammatory spinal arthritis will be listed on the Pharmaceutical Benefits Scheme from December 1.

Almost 4000 patients are expected to immediately benefit from the subsidised golimumab, which will be marketed under the name Simponi and works by blocking inflammation through changes to the patient’s immune system.

Read Herald Sun article